Serum metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 in lung carcinoma patients

Journal of Thoracic DiseaseDrzewiecka-Jedrzejczyk M, et al. | January 10, 2018

Advertisement

This study was designed to evaluate the prognostic value of matrix metalloproteinase (MMP)-2 and TIMP-2 concentrations in non-small cell lung carcinoma (NSCLC) patients. Findings demonstrated the correlation of serum MMP-2 and TIMP-2 concentrations with the tumour size and presence of metastases to lymph nodes. Data indicated that serum MMP-2 and TIMP-2 concentrations may serve as an auxiliary parameter indicating probability of a more advanced stage of lung cancer.

Read the full article on Journal of Thoracic Disease

Advertisement